STATEN ISLAND, N.Y., June 29, 2021 /PRNewswire/ — Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) (the “Company”), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today…
ACURX PHARMACEUTICALS, Inc. Announces Closing of INITIAL Public Offering OF common stock AND FULL EXERCISE OF UNDERWRITERS’ OPTION TO PURCHASE ADDITIONAL SHARES
Share this article
More News
Stock Market News and Research Tools
June 11, 2026
Can Nvidia be Considered a Growth Stock Anymore?
June 11, 2026
